Regenxbio (NASDAQ: RGNX)
Regenxbio Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Regenxbio Company Info
Regenxbio is the expert in adeno-associated virus (AAV) delivery of potentially curative gene therapies through its NAV technology platform.
News & Analysis
Does an FDA Fast Track Designation Make Regenxbio Stock a Buy Now?
The company focuses on using its technology for gene-editing therapies.
3 Small-Cap Medical Stocks With Big Momentum
Now is a good time to take a closer look at these stocks.
Why Regenxbio Stock Is Way Up Today
American biopharmaceutical giant AbbVie wants access to Regenexbio's gene therapy for macular degeneration.
Big Pharma Has Mad Love For These 2 Biotechs
These companies' collaborations with bigger businesses validates their science -- and paves the way for future revenues and profits.
3 Blindness-Fighting Biotech Stocks That Could Surge This Week
Here's what to look out for at the American Academy of Ophthalmology's annual meeting later this week.
3 Top Biotech Stocks to Buy Right Now
Patent cliffs and pipeline risks are among the reasons these biologic drug specialists are attractively priced today.
Approval of a Game-Changing Gene Therapy for SMA Delivers a Win for Novartis and Regenxbio
A $2.1 million price tag could make Zolgensma a blockbuster medicine for these companies.
3 Top Small-Cap Stocks to Buy Right Now
These three small-cap stocks have outstanding growth potential.
Valuation
Earnings Transcripts
REGENXBIO inc (RGNX) Q3 2021 Earnings Call Transcript
RGNX earnings call for the period ending September 30, 2021.
REGENXBIO inc (RGNX) Q2 2021 Earnings Call Transcript
RGNX earnings call for the period ending June 30, 2021.
Regenxbio Inc. (RGNX) Q1 2021 Earnings Call Transcript
RGNX earnings call for the period ending March 31, 2021.
Regenxbio Inc. (RGNX) Q4 2020 Earnings Call Transcript
RGNX earnings call for the period ending December 31, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.